The development of cancer therapies using monoclonal antibodies has been successful during the last 30 years. Recently much progress was achieved with technologies involving bispecific and multi-specific antibodies. Bispecific antibodies (BsAbs) are antibodies that bind two distinct epitopes, and a large number of potential clinical applications of BsAbs have been described. Here we review mechanism of action, clinical development and future challenges of BsAbs which could be a serve as a valuable arsenal in cancer patients.
Bibliographical noteFunding Information:
RAS- Advisory Board: Amgen, Astra-Zeneca, Bayer, BMS, Boehringer Ingelheim, Lilly, Merck, Novartis, Puma Biotechnology, Pfizer, Roche, Taiho, Takeda, Yuhan and research grants from Astra-Zeneca, Boehringer Ingelheim.
© 2021 Elsevier Ltd
All Science Journal Classification (ASJC) codes
- Radiology Nuclear Medicine and imaging